Communication about medications and diseases is a data-driven and often somewhat "dry" matter – especially for innovative new drugs and increasingly complex clinical studies. Here, good science communication is essential. A recently published study clearly showed: The way biopharma companies communicate scientific evidence is crucial for the success of a product launch.
The Veeva Pulse Field Trends Report from the USA examines introduction of cancer drugs and, according to the authors, is transferable to other therapies and regions. The results are obvious: Prelaunch communication by Medical Affairs can accelerate therapy introduction by 40 %!
An important finding was the enormous potential of young, digitally savvy doctors. These emerging experts are four times more likely to adopt a new treatment option than their more experienced colleagues. They participate twice as often in clinical studies or in the development of new medical guidelines. At the same time, they give more lectures at conferences, are published more frequently, and engage much more actively with their peers. It is therefore worthwhile for companies to specifically target these young KOLs.
But how do you find these rising stars? What topics are currently of great interest to them? Which experts should companies build relationships with early on?
Our innovative KOL mapping process "We. Xcelerate" combines the latest AI tools with the experience of our staff. This way, we can identify the rising stars before everyone knows them.
Contact us and let's identify the opinion leaders of tomorrow together. Discover your individual KOL starry sky.
You can find more factors that increase doctors' willingness to cooperate in our current Brands in Motion Health Report.
Bei der Verschreibung von Therapien orientieren sich Ärzt*innen in erster Linie an dem Nutzen-Risiko-Profil.
Aber ist das wirklich alles?
For biotech and pharmaceutical companies, maintaining a strong corporate reputation requires more than delivering high-quality, safe medicines.
New We. research shows prescribers are strongly influenced by pharmaceutical and biotech companies' reputation.
Bei der Verschreibung von Therapien orientieren sich Ärzt*innen in erster Linie an dem Nutzen-Risiko-Profil.
Aber ist das wirklich alles?
For biotech and pharmaceutical companies, maintaining a strong corporate reputation requires more than delivering high-quality, safe medicines.
New We. research shows prescribers are strongly influenced by pharmaceutical and biotech companies' reputation.
